drugset
drugset / Trial / NCT05081479

A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma

NCT05081479 ↗

Phase 1 Active not recruiting 9 enrolled Memorial Sloan Kettering Cancer Center
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to test the safety of N-AC when given in combination with Yescarta to people with lymphoma. This study will test different doses of N-AC to find the highest dose that causes few or mild side effects in participants.

Timeline

Start
2021-12-08
Primary completion
2026-10-21
Completion
2026-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule — Other

Indications

lymphoma